Elsevier Clinical Solutions Introduces Free Clinical Documentation Improvement Reference App for Apple and Android Phones and Tablets

PHILADELPHIA, July 15, 2014-- Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of the Elsevier Clinical Documentation Improvement (CDI) Reference App for Apple and Android phones and tablets. The free mobile app was created using ICD-10 coding requirements and developed specifically for physicians and clinical documentation specialists to help improve clinical documentation within the healthcare record. Using Elsevier original content, the Elsevier CDI Reference app is now available for free download via iTunes and Google Play.

The app enables clinicians to quickly and easily find the exact clinical terms or phrases to accurately describe a specific patient condition. Additionally, it will help demonstrate medical necessity for services, justify admission and treatment, and accurately reflect the severity of illness based on the patient's presentation. This allows the physician to document conditions correctly and creates a seamless handoff between the physician and the coder for payment.

"Providing physicians with a reference tool that emphasizes complete documentation while considering ICD-10-CM/PCS requirements will enable improved data quality to assist with defining excellent healthcare delivery, payment, compliance and quality reporting," said Deb Neville, Director of Revenue Cycle, Coding, and Compliance, Elsevier Clinical Solutions. "Eventually, improved patient care will result from the integration of concise information within the EHR by offering pertinent information from a single source."

The app focuses on 45 conditions that have the most compliance risk, changes to documentation requirements, payment or audit implications, or that generate the most queries for specification from coding staff. Examples of conditions include, Chest Pain and Angina, Dementia, Heart Failure, Kidney Disease, Myocardial Infarction, OB, Perinatal Care, Pneumonia, Sepsis and SIRS, Spinal Disorders, Syncope and Collapse, and Venous Thromboembolism.

Key documentation elements that are provided under each condition include:

  • Acuity
  • Designation of type of condition
  • Etiology
  • Associated conditions and manifestations
  • Clinical indicators
  • Staging
  • Treatments or interventions
  • Information unique to neonates or pediatric patients, if appropriate

For more information and to download the app, visit http://icd-10online.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Christopher Capot
Director, Corporate Relations
Elsevier
+1-212-633-3164
c.capot@elsevier.com

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.